ES2062155T3 - Composiciones para el tratamiento de neoplasia que contienen un agente antineoplasico y un agente protector reductor de efectos secundarios. - Google Patents
Composiciones para el tratamiento de neoplasia que contienen un agente antineoplasico y un agente protector reductor de efectos secundarios.Info
- Publication number
- ES2062155T3 ES2062155T3 ES90107246T ES90107246T ES2062155T3 ES 2062155 T3 ES2062155 T3 ES 2062155T3 ES 90107246 T ES90107246 T ES 90107246T ES 90107246 T ES90107246 T ES 90107246T ES 2062155 T3 ES2062155 T3 ES 2062155T3
- Authority
- ES
- Spain
- Prior art keywords
- side effects
- treatment
- agent
- antineoplastic
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE DESCRIBE UNA COMBINACION DE QUIMIOTERAPIA PARA TRATAMIENTO DE ENFERMEDADES NEOPLASICAS. LOS EFECTOS COLATERALES CITOTOXICOS ADVERSOS ASOCIADOS CON AGENTES ANTI-NEOPLASICOS SE PUEDEN REDUCIR POR EL USO DE UN COPOLIMERO CITOPROTECTOR EN COMBINACION CON EL AGENTE ANTI-NEOPLASICO. UNA COMBINACION PREFERIDA DE QUIMIOTERAPIA USA DOXORUBICINA PARA CONSEGUIR LA REDUCCION DEL TUMOR CON UN AGENTE CITOPROTECTOR PARA REDUCIR LOS EFECTOS TOXICOS COLATERALES ASOCIADOS CON LA DOXORUBICINA Y PARA MEJORAR LA ACTIVIDAD ANTI-NEOPLASICA DE LA DOXORUBICINA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33950389A | 1989-04-17 | 1989-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2062155T3 true ES2062155T3 (es) | 1994-12-16 |
Family
ID=23329296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES90107246T Expired - Lifetime ES2062155T3 (es) | 1989-04-17 | 1990-04-17 | Composiciones para el tratamiento de neoplasia que contienen un agente antineoplasico y un agente protector reductor de efectos secundarios. |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0393575B1 (es) |
JP (1) | JPH02292227A (es) |
AT (1) | ATE102838T1 (es) |
CA (1) | CA2014732A1 (es) |
DE (1) | DE69007319T2 (es) |
DK (1) | DK0393575T3 (es) |
ES (1) | ES2062155T3 (es) |
PT (1) | PT93772A (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9213077D0 (en) * | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
US5493017A (en) * | 1992-08-14 | 1996-02-20 | The Trustees Of The University Of Pennsylvania | Ring-metalated porphyrins |
US5371199B1 (en) * | 1992-08-14 | 1995-12-26 | Univ Pennsylvania | Substituted porphyrins porphyrin-containing polymers and synthetic methods therefor |
US5599924A (en) * | 1992-08-14 | 1997-02-04 | Trustees Of The University Of Pennsylvania | Electron-deficient porphyrins and processes and intermediates for preparing same |
US5817830A (en) * | 1992-08-14 | 1998-10-06 | Trustees Of The University Of Pennsylvania | Pyrrolic compounds |
US5378456A (en) * | 1993-03-25 | 1995-01-03 | American Cyanamid Company | Antitumor mitoxantrone polymeric compositions |
US5569667A (en) * | 1995-01-19 | 1996-10-29 | Warner-Lambert Company | Treatment of prostate cancer |
BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
CA2242406C (en) * | 1996-01-11 | 2009-09-08 | Peter Buhl Jensen | Topoisomerase ii poison and bis-dioxypiperazine derivative combination therapy |
US6265385B1 (en) | 1996-01-11 | 2001-07-24 | Topo Target Aps | Topoisomerase II poison and bis-dioxopiperazine derivative combination therapy |
ATE310505T1 (de) * | 1996-05-14 | 2005-12-15 | Stanislaw R Burzynski | Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität |
DE19636889A1 (de) | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
US5783689A (en) * | 1996-11-12 | 1998-07-21 | University Of Notre Dame | Antibacterial and antifungal nucleosides |
GB9804013D0 (en) | 1998-02-25 | 1998-04-22 | Sanofi Sa | Formulations |
AU780844B2 (en) * | 1999-10-12 | 2005-04-21 | Temple University-Of The Commonwealth System Of Higher Education | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
US6767926B1 (en) | 1999-10-12 | 2004-07-27 | Temple University - Of The Commonwealth System Of Higher Education | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
AT408719B (de) * | 2000-03-22 | 2002-02-25 | Nowicky Wassili | Mittel zur behandlung von hepatitis c |
IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
US20020128258A1 (en) * | 2001-03-09 | 2002-09-12 | Jean-Pierre Robin | Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives |
CA2466148C (en) | 2001-11-01 | 2013-01-08 | Spectrum Pharmaceuticals, Inc. | Medical compositions for intravesical treatment of bladder cancer |
US8563592B2 (en) | 2001-11-01 | 2013-10-22 | Spectrum Pharmaceuticals, Inc. | Bladder cancer treatment and methods |
WO2003053407A1 (en) * | 2001-12-19 | 2003-07-03 | Research Development Foundation | Liposomal delivery of vitamin e based compounds |
AU2003214462A1 (en) | 2002-04-03 | 2003-10-13 | Astrazeneca Ab | Indole derivatives having anti-angiogenetic activity |
FR2863892B1 (fr) * | 2003-12-18 | 2007-05-11 | Univ Paris Descartes | Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux |
WO2005111055A1 (ja) * | 2004-04-28 | 2005-11-24 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | 新規抗生物質キガマイシン類とその用途 |
US7250416B2 (en) | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
MY163296A (en) | 2011-08-30 | 2017-09-15 | Astex Pharmaceuticals Inc | Drug formulations |
WO2014179528A2 (en) * | 2013-05-01 | 2014-11-06 | Brown Dennis M | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions |
MX2018000016A (es) | 2015-07-02 | 2019-01-31 | Otsuka Pharma Co Ltd | Composiciones farmaceuticas liofilizadas. |
EP3661522A2 (en) | 2017-08-03 | 2020-06-10 | Otsuka Pharmaceutical Co., Ltd. | Drug compound and purification methods thereof |
CN116019798B (zh) * | 2022-07-20 | 2024-03-12 | 中南大学湘雅二医院 | 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4255537A (en) * | 1979-01-22 | 1981-03-10 | Monsanto Company | Polymeric immunoregulatory agents containing half-amide/half carboxy/imide groups |
-
1990
- 1990-04-16 PT PT93772A patent/PT93772A/pt not_active Application Discontinuation
- 1990-04-17 CA CA002014732A patent/CA2014732A1/en not_active Abandoned
- 1990-04-17 AT AT90107246T patent/ATE102838T1/de not_active IP Right Cessation
- 1990-04-17 EP EP90107246A patent/EP0393575B1/en not_active Expired - Lifetime
- 1990-04-17 DE DE69007319T patent/DE69007319T2/de not_active Expired - Fee Related
- 1990-04-17 JP JP2101530A patent/JPH02292227A/ja active Pending
- 1990-04-17 ES ES90107246T patent/ES2062155T3/es not_active Expired - Lifetime
- 1990-04-17 DK DK90107246.2T patent/DK0393575T3/da active
Also Published As
Publication number | Publication date |
---|---|
DE69007319T2 (de) | 1994-08-04 |
EP0393575B1 (en) | 1994-03-16 |
DK0393575T3 (da) | 1994-04-05 |
JPH02292227A (ja) | 1990-12-03 |
PT93772A (pt) | 1991-01-08 |
CA2014732A1 (en) | 1990-10-17 |
EP0393575A1 (en) | 1990-10-24 |
ATE102838T1 (de) | 1994-04-15 |
DE69007319D1 (de) | 1994-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2062155T3 (es) | Composiciones para el tratamiento de neoplasia que contienen un agente antineoplasico y un agente protector reductor de efectos secundarios. | |
EP2295063A3 (en) | Compositions and the use thereof the treatment of mitochondrial diseases | |
EP1370253B8 (en) | Use of alpha, beta unsaturated aryl sulfones for protecting cells and tissues from ionizing radiation toxicity | |
PT671910E (pt) | Utilizacao de derivados de adamantano no fabrico de um medicamento para o tratamento do glaucoma | |
LV10924A (lv) | Sintetiskie katalitiskie brivo radikalu akceptori kurus izmanto ka antioksidantus slimibu profilaksei un arstesanai | |
SE9301951D0 (sv) | Methods for administration of taxol | |
CO4410203A1 (es) | Formulaciones de analogos de insulina | |
IT1073647B (it) | Perfezionamento nei materiali di medicazione in particolare bende costituite da tre componenti,per l'applicazione sulla superficie di un corpo | |
ATE298577T1 (de) | Präparate auf purinbasis | |
EP0690722A4 (en) | COMPOSITION AND METHOD FOR REDUCING THE TOXICITY OF BIOLOGICALLY ACTIVE FACTORS | |
ES2036553T3 (es) | Composiciones farmaceuticas que tienen actividad antineoplastica. | |
WO2003049694A3 (en) | Methods of therapy for non-hodgkin's lymphoma | |
PL313223A1 (en) | Nigella sativa as a therapeutic agent | |
ES2062375T3 (es) | Composiciones farmaceuticas que contienen un complejo de zinc. | |
MX9205568A (es) | Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida. | |
ITRM910730A1 (it) | Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali. | |
GR3027569T3 (en) | Glycosyl-etoposide prodrugs, process for their preparation and their use in combination with functionalised tumour-specific enzyme conjugates | |
BE1000723A4 (fr) | Utilisation de gangliosides exogenes dans des maladies tumorales comme facteur de protection contre la toxicite de medicaments antitumoraux. | |
KR920017668A (ko) | 암 전이 억제 또는 예방 방법 및 이를 위한 제제 | |
DE3273389D1 (en) | Derivatives of pentacyclo undecanes, processes for preparing these compounds, and pharmeceutical compositions thereof | |
DE3163920D1 (en) | Pharmaceutical preparations comprising polyprenyl compounds, especially as anti-cancer agents, and pharmaceutical compositions for the prevention and treatment of cancer and skin diseases | |
ES2031462T3 (es) | Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima. | |
KR870010871A (ko) | 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법 | |
JPS55113721A (en) | Immunity regulator | |
BE894860A (fr) | Therapeutique adjuvante par agent progestatif |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 393575 Country of ref document: ES |